Indaptus Therapeutics appoints Tim Ruan and Dr. Yi Zhang to board; Matthew McMurdo resigns

Indaptus Therapeutics, Inc.

Appoints Tim Ruan as Class II director and Audit Committee member; qualifies as audit committee financial expert.
Appoints Dr. Yi Zhang as Class II director and Nominating Committee member.
Matthew McMurdo resigned as director on April 22, 2026; resignation not due to any disagreement.
Annual cash retainer for each new independent director is $30,000, payable quarterly, plus expense reimbursement.
Both new directors are independent under Nasdaq rules.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.